Prevention of hyaline membrane disease with plasminogen. Preliminary report of a cooperative study. 1976

C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub

Five hundred premature infants were treated in a double blind, randomized study with intravenous plasminogen or placebo within 60 minutes of birth. There was a significant decrease in severe clinical respiratory distress, death due to hyaline membrane disease and total mortality in the plasminogen treated infants as compared to the controls.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D010958 Plasminogen Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent. Profibrinolysin,Glu-Plasminogen,Glutamic Acid 1-Plasminogen,Glutamyl Plasminogen,1-Plasminogen, Glutamic Acid,Glu Plasminogen,Glutamic Acid 1 Plasminogen,Plasminogen, Glutamyl
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006819 Hyaline Membrane Disease A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS). Disease, Hyaline Membrane,Diseases, Hyaline Membrane,Hyaline Membrane Diseases

Related Publications

C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
February 1973, La Nouvelle presse medicale,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
May 1977, The Indian journal of medical research,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
March 1978, Pediatric annals,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
April 1973, British medical journal,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
July 1973, British medical journal,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
October 1972, Pediatrics,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
September 1986, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
June 1973, British medical journal,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
January 1980, Akusherstvo i ginekologiia,
C M Ambrus, and T S Choi, and E Cunnanan, and B Eisenberg, and H P Staub
January 1987, Intensive care medicine,
Copied contents to your clipboard!